Abstract | BACKGROUND: The emergence of resistance to available antiviral drugs may cause higher Cytomegalovirus (CMV)-associated morbidity and mortality in hematopoietic cell transplant (HCT) recipients. Few novel antiviral drugs are being developed with potential effect against refractory or resistant CMV infections. Brincidofovir, an oral nucleotide analog and prodrug of cidofovir, has shown in vitro activity against CMV. METHODS: We reviewed data of 4 cancer patients with resistant CMV or herpes simplex virus (HSV) infections and were treated with brincidofovir under emergency IND application. RESULTS: CONCLUSION:
|
Authors | Danielle El-Haddad, Firas El Chaer, Jackapat Vanichanan, Dimpy P Shah, Ella J Ariza-Heredia, Victor E Mulanovich, Alison M Gulbis, Elizabeth J Shpall, Roy F Chemaly |
Journal | Antiviral research
(Antiviral Res)
Vol. 134
Pg. 58-62
(10 2016)
ISSN: 1872-9096 [Electronic] Netherlands |
PMID | 27582067
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2016 Elsevier B.V. All rights reserved. |
Chemical References |
- Antiviral Agents
- Organophosphonates
- brincidofovir
- Cytosine
|
Topics |
- Aged
- Antiviral Agents
(therapeutic use)
- Clinical Trials as Topic
- Cytomegalovirus
(drug effects)
- Cytomegalovirus Infections
(drug therapy)
- Cytosine
(adverse effects, analogs & derivatives, therapeutic use)
- Drug Resistance, Viral
(genetics)
- Female
- Hematopoietic Stem Cell Transplantation
(adverse effects)
- Herpes Simplex
(drug therapy)
- Herpesviridae Infections
(drug therapy)
- Humans
- Immunocompromised Host
(drug effects)
- Male
- Middle Aged
- Neoplasms
(complications, immunology, virology)
- Organophosphonates
(adverse effects, therapeutic use)
|